Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Upstream Bio, Inc. ( (UPB) ) just unveiled an update.
Upstream Bio, Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025, where stockholders voted on two key proposals. The first proposal involved the election of Erez Chimovits and Marcella Kuhlman Ruddy as Class I directors, which was approved. The second proposal was the ratification of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, which was also ratified.
The most recent analyst rating on (UPB) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Upstream Bio, Inc. stock, see the UPB Stock Forecast page.
Spark’s Take on UPB Stock
According to Spark, TipRanks’ AI Analyst, UPB is a Neutral.
Upstream Bio, Inc. has a moderate stock score driven by strong technical analysis indicators suggesting positive momentum. However, the financial performance poses significant risks due to operational losses and negative cash flow. Valuation remains uncertain due to the lack of earnings and dividends, typical of a growth-phase biotechnology company.
To see Spark’s full report on UPB stock, click here.
More about Upstream Bio, Inc.
Average Trading Volume: 327,455
Technical Sentiment Signal: Hold
Current Market Cap: $623.5M
For detailed information about UPB stock, go to TipRanks’ Stock Analysis page.